ArticlePediatric pulmonology2026
Respiratory Outcomes in Children With Neonatal Respiratory Distress Syndrome and Monoallelic ABCA3 Variants.
Article in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionLung disease due to ABCA3 variants and resultant surfactant dysfunction is an autosomal recessive disease. However, monoallelic ABCA3 variants are overrepresented in term or late-preterm infants with non-fatal neonatal respiratory distress syndrome (RDS). The childhood respiratory outcomes of infants with monoallelic ABCA3 variants who present with neonatal RDS are unknown. In this study, we report the respiratory outcomes beyond neonatal hospitalization (median follow-up 1 year [range 1-9.4 years]) for infants with monoallelic ABCA3 variants and neonatal RDS.
methodsParticipants with monoallelic ABCA3 variants classified as pathogenic, likely pathogenic, or of uncertain significance with neonatal RDS identified in 3 cohorts (ChILD Registry n = 9, disease-based cohort n = 19, and nested case-control n = 20) were included in this retrospective, descriptive study. The primary outcome was duration of supplemental oxygen use. Secondary outcomes included respiratory morbidities after NICU discharge.
resultsOf 48 infants who met inclusion criteria, 8 (17%) were discharged home on supplemental oxygen, including two who required home invasive mechanical ventilation. The ABCA3 pathogenic variant p.Glu292Val was the most common variant identified in the infants who required oxygen beyond NICU discharge (6 of 8). Oxygen was discontinued by 10 months of age in 50% of infants discharged from birth hospitalization on oxygen. Respiratory morbidities, including hospitalizations (62% vs. 8%, p = 0.005) and emergency department (ED) visits (71% vs. 35%, p < 0.01), were more common among participants discharged home on oxygen compared to those discharged home without oxygen.
conclusionsThese findings suggest that infants with monoallelic ABCA3 variants and neonatal RDS may require prolonged home oxygen or mechanical ventilation and experience increased risk for respiratory morbidities, including subsequent hospitalization and ED visits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.